Polymorphisms of CYP11A1 have been detected as potential markers in different hormone-dependent diseases, including breast cancer [16–19], polycystic ovary syndrome (PCOS) [21], prostate cancer [22,23], and endometrial cancer [24]. This evidence concerns the gene CYP11A1 and breast carcinoma.